Lanvin Group Holdings Limited filed a Form 6-K on November 13, 2026, disclosing that the company received a written notice from the New York Stock Exchange on November 10, 2026, stating it is not in compliance with the exchange's minimum share price listing standard.

Key Highlights

  • Notice received November 10, 2026: NYSE notified Lanvin Group that its ordinary shares averaged below US$1.00 per share over a consecutive 30 trading-day period, triggering a non-compliance finding under Section 802.01C of the NYSE Listed Company Manual.
  • Six-month cure period: The company has six months from receipt of the notice to regain compliance with the minimum share price requirement.
  • Compliance conditions: To cure the deficiency, the ordinary shares must close at or above US$1.00 per share and average at least US$1.00 per share over the 30 trading-day period ending on the last trading day of any calendar month within the cure period.
  • Delisting risk if cure fails: If compliance is not regained by the end of the cure period, the NYSE stated it will commence suspension and delisting procedures for the ordinary shares.
  • No immediate trading impact: According to the filing, the notice has no immediate effect on the listing or trading of the ordinary shares, which continue to trade on NYSE under the symbol "LANV."
  • No default triggered: The filing states the notice "does not conflict with or cause an event of default under any of the Company's material debt or other agreements."

Lanvin Group Discloses NYSE Minimum Price Non-Compliance and Cure Timeline

According to the Form 6-K filed with the U.S. Securities and Exchange Commission, Lanvin Group Holdings Limited (NYSE:LANV) received a written notice from the NYSE on November 10, 2026, indicating that the company is not in compliance with Section 802.01C of the NYSE Listed Company Manual. The notice was triggered because the average closing price of the company's ordinary shares fell below US$1.00 per share over a consecutive 30 trading-day period.

The filing states that the company notified the NYSE, within ten business days of receipt of the notice, of its intent to cure the deficiency and regain compliance with the exchange's continued listing standards. Under the applicable NYSE rule, the company has a six-month cure period in which to satisfy the minimum price requirement. Compliance can be regained at any time during that period if, on the last trading day of any calendar month within the cure period, the ordinary shares close at or above US$1.00 per share and maintain an average closing price of at least US$1.00 per share over the preceding 30 trading days. If compliance is not restored by the end of the cure period, the NYSE will commence suspension and delisting procedures.

The company disclosed that the notice is "not anticipated to impact the Company's ongoing business operations or its reporting requirements" with the SEC. The filing further states that the notice does not constitute or cause an event of default under any of the company's material debt or other agreements. The ordinary shares remain listed and traded on the NYSE under the symbol "LANV" during the cure period, subject to the company's continued compliance with other NYSE listing standards. The company issued a press release on November 13, 2026, announcing receipt of the notice; a copy is furnished as Exhibit 99.1 to the Form 6-K.

What Was Disclosed

Lanvin Group Holdings Limited reported receiving an NYSE non-compliance notice on November 10, 2026, related to its ordinary shares averaging below US$1.00 over 30 consecutive trading days. The company has six months to cure the deficiency or face potential suspension and delisting.